1. Scrip
  2. >>Business
  3. >>Financing

ElevateBio Brings Centralized Model To Cell And Gene Therapy

 
• By Mandy Jackson

The company run by former Alexion and bluebird executives raised $150m and will build an R&D and manufacturing facility to serve its own start-ups and strategic partners, centralizing capabilities that would take individual firms millions of dollars and years to develop for a single product.

ElevateBio exterior camp base buidling 2
BaseCamp will be ElevateBio's cell and gene therapy hub. • Source: ElevateBio

ElevateBio LLC executives have been working for about a year on a cell and gene therapy strategy that they brought out of stealth mode on 13 May with the announcement that they raised $150m in series A venture capital. The funding will mainly go to building research and development and manufacturing capabilities, but also to fund small subsidiaries based on individual R&D programs and platforms.

The firm's hub-and-spoke model – a structure that involves a centralized entity spinning out multiple product- or platform-specific start-ups –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.